RT Journal Article
T1 A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
A1 Carmona Bayonas, Alberto
A1 Pérez Segura, Pedro
A1 Ortega Morán, Laura
A1 Muñoz Martín, Andrés Jesús
AB Background: The ever-growing complexity of cancer-associated thrombosis (CAT), with new antineoplastic drugs and anticoagulants, distinctive characteristics, and decisions with low levels of evidence, justifies this registry. Method: TESEO is a prospective registry promoted by the Spanish Society of Medical Oncology to which 34 centers contribute cases. It seeks to provide an epidemiological description of CAT in Spain. Results: Participants (N=939) with CAT diagnosed between July 2018 and December 2019 were recruited. Most subjects had advanced colon (21.4%), non-small cell lung (19.2%), and breast (11.1%) cancers, treated with dual-agent chemotherapy (28.4%), monochemotherapy (14.4%), or immune checkpoint inhibitors (3.6%). Half (51%) were unsuspected events, albeit only 57.1% were truly asymptomatic. Pulmonary embolism (PE) was recorded in 571 (58.3%); in 120/571 (21.0%), there was a concurrent deep venous thromboembolism (VTE). Most initially received low molecular weight heparin (89.7%). Suspected and unsuspected VTE had an OS rate of 9.9 (95% CI, 7.3-non-computable) and 14.4 months (95% CI, 12.6-non-computable) (p=0.00038). Six-month survival was 80.9%, 55.9%, and 55.5% for unsuspected PE, unsuspected PE admitted for another reason, and suspected PE, respectively (p<0.0001). The 12-month cumulative incidence of venous rethrombosis was 7.1% (95% CI, 4.7-10.2) in stage IV vs 3.0% (95% CI, 0.9-7.1) in stages I-III. The 12-month cumulative incidence of major/clinically relevant bleeding was 9.6% (95% CI, 6.1-14.0) in the presence of risk factors. Conclusion: CAT continues to be a relevant problem in the era of immunotherapy and targeted therapies. The initial TESEO data highlight the evolution of CAT, with new agents and thrombotic risk factors.
PB Elsevier
SN 0953-6205
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/126192
UL https://hdl.handle.net/20.500.14352/126192
LA eng
NO Carmona-Bayonas A, Gómez D, Martínez de Castro E, Pérez Segura P, Muñoz Langa J, Jimenez-Fonseca P, Sánchez Cánovas M, Ortega Moran L, García Escobar I, Rupérez Blanco AB, Fernández Pérez I, Martínez de Prado P, Porta I Balanyà R, Quintanar Verduguez T, Rodríguez-Lescure Á, Muñoz A. A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry. Eur J Intern Med. 2020 Aug;78:41-49
NO Sanofi, S.A.
DS Docta Complutense
RD 30 dic 2025